IDiyas

For the Inventor, By the Inventor

Thousand Oaks, CA, United States of America

Randy Ira Hecht

USPTO Granted Patents = 19 


 

Average Co-Inventor Count = 6.3

ph-index = 9

Forward Citations = 421(Granted Patents)


Location History:

  • Thousand Oaks, CA (US) (2005 - 2016)
  • Raleigh, NC (US) (2016 - 2023)

Company Filing History:

goldMedal18 out of 1,970 
 
Amgen Inc.
 patents
silverMedal1 out of 832,680 
Other
 patents

Years Active: 2005-2023

Loading Chart...
Loading Chart...
Loading Chart...
19 patents (USPTO):
1. 11840558 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2023-12-12),
2. 11072640 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2021-07-27),
3. 10189890 - Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods (2019-01-29),
4. 10011642 - Methods of treating of diabetes and obesity using FGF21 mutants (2018-07-03),
5. 9493530 - FGF21 mutants comprising a mutation at position 98, 171 and/or 180 (2016-11-15),
6. 9279013 - FGF-21 mutants comprising polyethylene glycol and uses thereof (2016-03-08),
7. 9273106 - FGF mutants with reduced proteolysis and aggregation (2016-03-01),
8. 8835385 - FGF21 polypeptides comprising two or more mutations and uses thereof (2014-09-16),
9. 8795985 - FGF 21 polypeptides comprising two or more mutations and uses thereof (2014-08-05),
10. 8642546 - FGF21 mutant fusion polypeptides and uses thereof (2014-02-04),
11. 8618053 - FGF21 mutants multimers and uses thereof (2013-12-31),
12. 8410051 - FGF21 mutants and uses thereof (2013-04-02),
13. 8361963 - Uses of FGF21 polypeptides comprising two or more mutations (2013-01-29),
14. 8188040 - FGF21 mutants and uses thereof (2012-05-29),
15. 8080254 - OB fusion protein compositions and methods (2011-12-20),

Title: Unveiling the Innovation Journey of Randy Ira Hecht

Introduction:

Randy Ira Hecht, a prolific inventor based in Thousand Oaks, CA (US), has made significant contributions to the field of biotechnology with his groundbreaking patents. With a total of 18 patents under his belt, Randy's work showcases his dedication to advancing medical treatments and therapies.

Latest Patents:

Randy's latest patents highlight his focus on pioneering treatments for non-alcoholic steatohepatitis (NASH) and advancements in the development of tissue inhibitor of metalloproteinase type three (TIMP-3) variants. His inventions revolve around utilizing FGF21 mutant polypeptides for treating NASH and exploring novel TIMP-3 muteins for various applications.

Career Highlights:

Throughout his career, Randy has demonstrated a keen aptitude for innovation and problem-solving. His patents not only reflect his scientific acumen but also his commitment to improving healthcare outcomes for patients worldwide. Randy's relentless pursuit of excellence has established him as a leading figure in the biotechnology industry.

Collaborations:

In his pursuit of groundbreaking inventions, Randy has collaborated with distinguished individuals in the field. Noteworthy among his coworkers are Edward John Belouski and Mark Leo Michaels, who have played integral roles in supporting Randy's innovative endeavors. Together, they have spearheaded novel research initiatives and pushed the boundaries of scientific discovery.

Conclusion:

Randy Ira Hecht's inventive spirit and remarkable achievements underscore his status as a visionary inventor in the realm of biotechnology. His dedication to advancing medical treatments and therapies serves as a testament to his enduring legacy in the field. As Randy continues to push the boundaries of innovation, the world eagerly anticipates his next groundbreaking invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…